---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-027041"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:59:30.649469+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Windtree Q3 net loss $4.1M, licenses KL4 surfactant globally for up to $78.9M milestones

## Summary
- Net loss of $4.1M ($0.13 per share) vs $8.2M loss in Q3 2021; operating loss $4.7M vs $8.1M.
- R&D expenses fell to $1.5M from $4.7M as focus shifts to istaroxime; G&A decreased to $2.7M.
- Global license to Lee's (HK)/Zhaoke for KL4 surfactant platform; up to $78.9M milestones plus double-digit royalties.
- Cash $8.4M at Sept 30, expected to fund operations into Q2 2023.
- USPTO allowed istaroxime patent for longer infusions; positive SEISMiC study published in European Journal of Heart Failure.

## SEC filing metadata
- accession: 0001437749-22-027041
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774922027041/0001437749-22-027041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774922027041/wint20220823_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-027041
- JSON: https://secwatch.observer/filing/0001437749-22-027041.json
- Plain text: https://secwatch.observer/filing/0001437749-22-027041.txt

## Key facts
- Earnings Releases
  WINDTREE THERAPEUTICS INC /DE/ reported third quarter ended September 30, 2022 results: net income $4.1 million, EPS ($0.13 per basic share).
  - Period: third quarter ended September 30, 2022
  - Net income: $4.1 million
  - EPS: ($0.13 per basic share)
  - Result: reported results
  source text: The Company reported a net loss of $4.1 million ( $0.13 per basic share) on 31.1 million weighted-average common shares outstanding for the quarter ended September 30, 2022 , compared to a net loss of $8.2 million ( $0.31 per basic share) on 26.7 million weighted average common shares outstanding for the comparable period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774922027041/0001437749-22-027041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.